Crescent Biopharma
CBIO
78 hedge funds and large institutions have $535M invested in Crescent Biopharma in 2019 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 24 increasing their positions, 32 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
1% more funds holding
Funds holding: 77 → 78 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.01% less ownership
Funds ownership: 1.05% → 1.04% (-0.01%)
6% less capital invested
Capital invested by funds: $567M → $535M (-$31.6M)
25% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 32
95% less call options, than puts
Call options by funds: $74K | Put options by funds: $1.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$57M |
| 2 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$4.32M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.7M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
+$1.7M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$4.31M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.88M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.42M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.15M |
CBIO Hedge Fund Activity: Q2 2019 in Review
78 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2019, worth a combined $535M — down 5.6% from $567M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CBIO positions and 6 closed out — a net gain of 4 holders — while 24 added to existing stakes and 32 trimmed.
The largest buyer was Invesco, opening a new position worth an estimated $57M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.54M.
- 78 institutional investors held Crescent Biopharma (CBIO) as of Q2 2019, up from 77 in Q1 2019.
- Funds reported $535M of Crescent Biopharma stock for Q2 2019, down 5.6% quarter-over-quarter.
- 10 funds opened new Crescent Biopharma positions in Q2 2019 and 6 closed out, a net change of +4 holders.
- The largest Crescent Biopharma buyer in Q2 2019 was Invesco, an estimated $57M added.
- The largest Crescent Biopharma seller in Q2 2019 was T. Rowe Price Associates, an estimated $4.54M sold.
Based on aggregated 13F filings for Q2 2019.